Regulus Therapeutics, the Carlsbad, CA-based developer of drugs that block microRNA targets, said today it has reached the first milestone as part of its partnership with GlaxoSmithKline. Regulus has delivered specific microRNA blockers, known as anti-MIRs, in mice, and shown how they change the expression of genes in immune cells. Regulus didn’t disclose any financial terms related to reaching the milestone. Regulus was founded as a joint venture of Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: [[ticker:ISIS]]) and Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]).
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
